ASH 2023: Clinical Implications for New Geriatric Assessment Tools in DLBCL

Suchitra Sundaram, MD

December 29, 2023

Suchitra Sundaram, MD, reflects on a prospective study presented at ASH 2023 that investigated the use of geriatric assessment tools to better gauge which patients with non-Hodgkin lymphoma will experience treatment toxicities.

In exploring the use of geriatric assessment tools to predict treatment toxicities, Dr Sundaram highlights the significance of tests like the Karnofsky Performance Scale Index and the Timed Up and Go test. Drawing on a clinical scenario, Dr Sundaram notes that the data serve as a reminder of the heterogeneity of older adult populations and the need to tailor treatment on the basis of factors other than age alone.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: ASH 2023: Clinical Implications for New Geriatric Assessment Tools in DLBCL - Medscape - Dec 29, 2023.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

ASH 2023: Clinical Implications for New Geriatric Assessment Tools in DLBCL

Tables

Authors and Disclosures

Authors and Disclosures

Expert

Suchitra Sundaram, MD

Comments

Email This

Feedback